SANTA CRUZ BIOTECHNOLOGY, INC.

Elongin A (1-300):sc-4323 WB

BACKGROUND

Individuals harboring germline mutations in the tumor suppressor gene von Hippel-Lindau (VHL) exhibit an increased susceptibility to a variety of tumors including renal carcinoma, hemangio-blastoma of the central nervous system and pheochromo-cytoma. The Elongin (SIII) complex has been identified as the functional target of the VHL protein. Elongin (SIII) is a heterotrimer composed of a transcriptional active subunit designated Elongin A and two regulatory subunits designated Elongin B and Elongin C. VHL functions by binding to the Elongin B and C subunits, inhibiting the transcriptional efficacy of the Elongin (SIII) complex. The VHL protein migrates with an apparent molecular weight of 38 kDa. The Elongin A subunit is 773 amino acids in length and has an apparent molecular weight of 110 kDa, while Elongin B and C are 18 kDa and 15 kDa proteins, respectively.

REFERENCES

1. Garrett, K.P., Tan, S., Bradsher, J.N., Lane, W.S., Conaway, J.W., and Conaway, R.C. 1994. Molecular cloning of an essential subunit of RNA polymerase II elongation factor SIII. Proc. Natl. Acad. Sci. USA 91: 5237-5241.
2. Krumm, A. and Groudine, M. 1995. Tumor suppression and transcription elongation: the dire consequences of changing partners. Science 269: 1400-1401.
3. Duan, D.R., Pause, A., Burgess, W.H., Aso, T., Chen, D.Y.T., Garrett, K.P., Conaway, R.C., Conaway, J.W., Linehan, W.M., and Klausner, R.D. 1995. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269: 1402-1406.
4. Aso, T., Lane, W.S., Conaway, J.W., and Conaway, R.C. 1995. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 269: 1439-1443.
5. Gross, D.J., Avishai, N., Meiner, V., Filon, D., Zbar, B., and Abeliovich, D. 1996. Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. J. Clin. Endocrin. Metab. 81: 147-149.
6. Waber, P.G., Lee, N.K., and Nisen, P.D. 1996. Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the von Hippel-Lindau tumor suppressor gene in head and neck cancer. Oncogene 12: 365-369.
7. Yamazaki, K., et al. 2003. Mammalian elongin A is not essential for cell viability but is required for proper cell cycle progression with limited alteration of gene expression. J. Biol. Chem. 278: 13585-13589.
8. Tamura, K., et al. 2003. Identification of EloA-BP1, a novel Elongin A binding protein with an exonuclease homology domain. Biochem. Biophys. Res. Commun. 309: 189-195.

SOURCE

Elongin A (1-300) is expressed in *E. coli* as a 60 kDa tagged fusion protein corresponding to amino acids 1-300 of Elongin A of human origin.

STORAGE

Store at -20° C; stable for one year from the date of shipment.

PRODUCT

Elongin A (1-300) is purified from bacterial lysates (>98%) by column chromatography; supplied as 10 µg in 0.1 ml SDS-PAGE loading buffer.

APPLICATIONS

Elongin A (1-300) is suitable as a Western blotting control for sc-11446.

RESEARCH USE

For research use only, not for use in diagnostic procedures.